NCT02377362View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

PHASE1TerminatedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 9, 2016

Study Completion Date

November 9, 2016

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GLWL-01, Part A

Capsules administered orally, in 2 out of 3 periods

DRUG

Placebo, Part A

Capsules administered orally in 1 out of 3 periods

DRUG

GLWL-01, Part B

Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28

DRUG

Placebo, Part B

Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28

DRUG

GLWL-01, Part C

Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28

DRUG

Placebo, Part C

Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28

Trial Locations (4)

33014

Clinical Pharmacology of Miami, Inc., Miami

78229

Clinical Trials of Texas, Inc., San Antonio

85283

Celerion, Tempe

91911

Profil Institute for Clinical Research, Inc., Chula Vista

Sponsors

Lead Sponsor

GLWL Research Inc.
All Listed Sponsors
lead

GLWL Research Inc.

OTHER

NCT02377362 - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01 | Biotech Hunter | Biotech Hunter